Search Results

PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile

Authors: Kouvelas, D.; Goulas, A.; Papazisis, G.; Sardeli, C.; Pourzitaki, C.

Source: Current Pharmaceutical Design, Volume 15, Number 30, October 2009 , pp. 3464-3475(12)

Publisher: Bentham Science Publishers

Sildenafil: A Review of its Use in Pulmonary Arterial Hypertension

Authors: Croom, Katherine F.; Curran, Monique P.

Source: Drugs, Volume 68, Number 3, 2008 , pp. 383-397(15)

Publisher: Adis International

Pfizer has launched sildenafil [Revatio] for the treatment of pulmonary arterial hypertension (PAH) in the UK

Source: Inpharma, Volume 1, Number 1528, 2006-03-11 , pp. 18-18(1)

Publisher: Adis International

Sildenafil for pulmonary arterial hypertension

Authors: Bartolome, Sonja D; Channick, Richard N

Source: Future Cardiology, Volume 2, Number 2, March 2006 , pp. 137-143(7)

Publisher: Future Medicine

Pfizer has announced that sildenafil [Revatio] has been approved in the EU

Source: Inpharma, Volume 1, Number 1513, 2005-11-12 , pp. 18-18(1)

Publisher: Adis International